Experimental Alzheimer’s Drug Said to Succeed in Slowing Cognitive Decline
An experimental Alzheimer’s drug developed by Eisai and Biogen significantly slowed cognitive and functional decline in a large trial of patients in the early stages of the disease, the companies said Tuesday. The injected drug, lecanemab, slowed progress of the brain-wasting disease by 27% compared with a placebo, meeting the study’s main goal and offering an apparent win for the companies and potentially for patients and their families desperate for an effective treatment. Eisai said the results from the 1,800-patient trial prove the longstanding theory that removal of sticky deposits of a protein called amyloid beta from the brains of